Irhythm Technologies Inc (NASDAQ:IRTC) CFO Matthew C. Garrett sold 1,193 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $55.00, for a total value of $65,615.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Irhythm Technologies Inc (NASDAQ IRTC) traded up $0.02 during midday trading on Wednesday, hitting $52.31. The company had a trading volume of 225,500 shares, compared to its average volume of 263,548. The company has a current ratio of 7.65, a quick ratio of 7.57 and a debt-to-equity ratio of 0.38. Irhythm Technologies Inc has a 52 week low of $24.25 and a 52 week high of $57.90.

Irhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.05. The business had revenue of $25.04 million for the quarter, compared to analyst estimates of $24.30 million. Irhythm Technologies had a negative return on equity of 27.67% and a negative net margin of 27.56%. Irhythm Technologies’s revenue was up 49.2% compared to the same quarter last year. During the same period last year, the firm posted ($2.80) earnings per share. equities analysts anticipate that Irhythm Technologies Inc will post -1.17 EPS for the current year.

Several research analysts have weighed in on IRTC shares. Canaccord Genuity increased their price objective on Irhythm Technologies from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, September 22nd. Zacks Investment Research cut Irhythm Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Morgan Stanley increased their price objective on Irhythm Technologies from $50.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada started coverage on Irhythm Technologies in a research report on Monday. They set an “outperform” rating and a $79.00 price objective on the stock. Finally, ValuEngine upgraded Irhythm Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, October 21st. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $65.25.

A number of large investors have recently added to or reduced their stakes in IRTC. Legal & General Group Plc boosted its stake in Irhythm Technologies by 131.0% in the second quarter. Legal & General Group Plc now owns 3,373 shares of the company’s stock valued at $143,000 after buying an additional 1,913 shares in the last quarter. Advisor Group Inc. boosted its stake in Irhythm Technologies by 763.9% in the third quarter. Advisor Group Inc. now owns 2,920 shares of the company’s stock valued at $151,000 after buying an additional 2,582 shares in the last quarter. First Mercantile Trust Co. acquired a new stake in Irhythm Technologies in the second quarter valued at about $221,000. Voya Investment Management LLC acquired a new stake in Irhythm Technologies in the second quarter valued at about $274,000. Finally, GSA Capital Partners LLP acquired a new stake in Irhythm Technologies in the second quarter valued at about $289,000. 97.80% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Irhythm Technologies Inc (IRTC) CFO Matthew C. Garrett Sells 1,193 Shares” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://theolympiareport.com/2017/12/06/irhythm-technologies-inc-irtc-cfo-matthew-c-garrett-sells-1193-shares.html.

Irhythm Technologies Company Profile

iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.

Insider Buying and Selling by Quarter for Irhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for Irhythm Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.